
Merck, Hengrui Launch Up-to-$2B+ Cardiometabolic Collaboration
Merck & Co. has agreed to license the oral small molecule Lipoprotein(a) [Lp(a)] inhibitor HRS-5346 from Jiangsu Hengrui Pharmaceuticals, through a licensing agreement that could generate up to $2 billion plus for the Chinese drug developer. Hengrui …